Glioblastoma (GBM) is the most common and lethal primary brain tumour in adults. Currently, the most effective treatment strategy for newly diagnosed GBM is surgical resection followed by radiotherapy and temozolomide (TMZ) chemotherapy ([@bib40]). However, the median overall survival is only 14.6 months; treatment failures often result from the development of TMZ chemoresistance, which is mediated by multiple signalling pathways ([@bib18]; [@bib42]). Genetic and epigenetic factors -- especially tumour protein (TP) 53 and *O*^6^-methylguanine DNA methyltransferase (MGMT) -- determine the sensitivity of glioma to TMZ and consequent apoptosis ([@bib39]). To increase the therapeutic efficacy of TMZ, the mechanism of TMZ-induced glioma cell death must be clarified so that it can serve as a basis to develop new treatment approaches.

We previously demonstrated that nuclear factor of activated T cells (NFAT) 1 is highly expressed in GBM cells ([@bib41]). Moreover, hyper-activation of NFAT1 leads to the upregulation of FasL and induces GBM cell death in a manner similar to activation-induced cell death (AICD) in mature lymphocytes ([@bib20]). The activation and nuclear translocation of NFATs are inhibited by glycogen synthase kinase (GSK)-3 ([@bib12]). Therefore, targeting GSK-3 and NFAT1 activity to induce an AICD-like process in gliomas is a novel approach to GBM treatment.

Lithium (Li) has long been used for the clinical treatment of mood disorders ([@bib28]). Li directly inhibits GSK-3 and activates the NFAT1/FasL-mediated apoptosis pathway in many cell types ([@bib16]; [@bib5]). It was recently reported that Li concentrations \>5 m[M]{.smallcaps} can affect the proliferation, apoptosis and migration of glioma cells via GSK-3 inhibition ([@bib34]; [@bib10]; [@bib15]; [@bib4]). However, the therapeutic window of Li is 0.6--1.4 m[M]{.smallcaps}, and serum levels \>1.5 m[M]{.smallcaps} are correlated with progressive toxicity, ultimately leading to neurological impairment ([@bib46]; [@bib16]). As such, administering high doses of Li is unfeasible, while lowering the therapeutic dose remains a clinical challenge.

Temozolomide has been shown to activate AKT ([@bib42]; [@bib47]), leading to the phosphorylation and deactivation of GSK-3 in glioma cells ([@bib42]), which could further activate NFATs. Moreover, TMZ triggers apoptosis in TP53 wild type and mutant (TP53wt and TP53mut, respectively) glioma cells. In the former, Fas receptor is activated and induces cell death in response to TMZ treatment in contrast to TP53mut cells ([@bib39]). We therefore speculated that TMZ combined with a low dose of Li could hyperactivate NFAT1/FasL signalling via GSK-3 inhibition. We investigated this possibility in the present study using TP53wt GBM cells and in a mouse xenograft model of GBM.

Materials and methods
=====================

Cell culture
------------

Human TP53wt U87 and TP53mut U251 GBM cells with methylated *MGMT* promoters ([@bib30]; [@bib14]; [@bib18]; [@bib8]) were purchased from the Chinese Academy of Sciences cell bank (Shanghai, China). U87 cells have wild-type *isocitrate dehydrogenase* (*IDH*) with a mutated *telomerase reverse transcriptase* (*TERT*) promoter and contain 1p19q co-deletion. U251 cells are *IDH* wild type with a mutated *TERT* promoter and non-1p19q co-deletion. Molecular features of U87 and U251 cells were determined by GenomiCare Biotechnology (Shanghai, China) and are consistent with previous reports ([@bib29]; [@bib45]; [@bib21]). Primary G1 and G2 GBM cells were derived from fresh clinical samples obtained from a 72-year-old female and a 54-year-old male GBM patient, respectively. G1 and G2 cell lines were established and neurosphere culture was performed as previously described by our group ([@bib17]). Tumour samples were analysed by Sanger sequencing and pyrosequencing (YuanQi Bio, Shanghai, China). G1 cells were TP53wt with an unmethylated *MGMT* promoter and G2 cells were TP53mut with an unmethylated MGMT promoter. In addition, both G1 and G2 cells were IDH wild type with a mutated *TERT* promoter and non-1p19q co-deletion. Molecular parameters of these GBM cells are described in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}. This study was approved by the institutional review board of our hospital, and written informed consent was obtained from each glioma tissue donor, who consented to the use of the tumour tissue and clinical data for future research.

Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and antibiotics (penicillin and streptomycin, 100 U ml^−1^ each) at 37 °C and 5% CO~2~.

Cell viability assay
--------------------

Cells were seeded in 96-well plates at a density of 1 × 10^4^ cells per well. The following day, cells were subjected to serum starvation overnight, and then treated with 1.2 m[M]{.smallcaps} LiCl (Sigma-Aldrich, St Louis, MO, USA) and/or 70 *μ*[M]{.smallcaps} TMZ (Sigma-Aldrich) for 24, 48, 72 or 96 h. In a subset of cultures, cells were pre-incubated with 10 *μ*g ml^−1^ FasL-neutralising antibody (AF126; Research Diagnostics, Flanders, NJ, USA) for 24 h before TMZ+Li administration. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay was used to evaluate cell proliferation according to the manufacturer's protocol. Cells were also quantified by cell counts using a haemocytometer after trypan blue staining.

Neurosphere formation assay
---------------------------

Cells were dissociated from neurospheres and seeded at 200 cells per well in 24-well plates and treated or left untreated as described above, and then cultured under neurosphere conditions for 7 days. Formed neurospheres were counted and are reported as the percentage of neurosphere-forming cells out of the total number of cells (i.e., 200). Neurospheres were immunolabelled with an anti-CD133 antibody (1 : 100, 293C3; Miltenyi Biotec, Auburn, CA, USA).

Detection of apoptosis by flow cytometry
----------------------------------------

To evaluate the sub-G0 DNA content, cells were stained with propidium iodide (PI, 75 *μ*[M]{.smallcaps}) in PBS containing 0.1% Nonidet P-40. DNA content was determined by flow cytometry using a FACScalibur instrument and CellQuest software (BD Biosciences, San Jose, CA, USA). The percentage of apoptotic cells was also determined with a fluorescein isothiocyanate-Annexin V Apoptosis Detection kit (BD Biosciences) according to the manufacturer's instructions.

Terminal deoxynucleotidyl transferase dUTP nick end labelling assay
-------------------------------------------------------------------

Apoptotic cells were detected by terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) using the TdT-FragEL DNA Fragmentation Detection kit (QIA33; Merck, Darmstadt, Germany) according to the manufacturer's instructions. Terminal deoxynucleotidyl transferase dUTP nick end labelling-positive cells were counted under an epifluorescence microscope. Cells with green fluorescence were defined as apoptotic and the rate of apoptosis was calculated according to the following formula: positive cells/(positive cells+negative cells) × 100%.

Transmission electron microscopy analysis
-----------------------------------------

Cells were fixed with 2.5% glutaraldehyde, washed and post-fixed in osmium tetroxide. Samples were dehydrated in a graded series of ethanol, stained with uranyl acetate and embedded in culture dishes. Ultra-thin sections of the cured blocks were cut using a diamond knife, and sections were stained with lead citrate and visualised by a transmission electron microscope (1200-EX; JEOL, Tokyo, Japan).

Western blotting
----------------

Total protein was extracted from cells using lysis buffer. To assess NFAT1 nuclear translocation, cytoplasmic and nuclear fractions were prepared as previously described ([@bib13]; [@bib16]). Equal amounts of protein from each sample were separated by electrophoresis and transferred to a nitrocellulose membrane, which was blocked and incubated overnight at 4 °C with antibodies against GSK-3*α*/*β* (D75D3; Cell Signaling Technology, Beverly, MA, USA), pSer21/9-GSK-3*α*/*β* (D17D2; Cell Signaling Technology), p53 (ab1101; Abcam, Cambridge, UK), Fas (ab103551; Abcam), NFAT1 (ab2722; Abcam) and FasL (all at 1 : 1000 dilution). The membrane was then incubated with the appropriate secondary antibody. Protein bands were detected using an enhanced chemiluminescence kit (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and band intensity was quantified using Sigma-Gel software (Jandel Scientific Software, Sari Kafael, CA, USA).

Immunocytochemistry
-------------------

Cells grown on coverslips were washed, fixed, blocked and incubated with an antibody against NFAT1 (1 : 100). Following treatment with a fluorophore-conjugated secondary antibody and nuclear counterstaining with Hoechst 33342, the coverslips were mounted on glass slides and cells were visualised and imaged with a confocal microscope (Olympus FV1000S-SIM; Olympus, Tokyo, Japan).

NFAT1 and p53 gene knockdown
----------------------------

Short hairpin (sh)RNA-mediated gene knockdown was carried out as previously described ([@bib20]; [@bib41]). A plasmid encoding shRNAs targeting *NFAT1* or *p53* or a control shRNA plasmid (Santa Cruz Biotechnology) was transfected into U87 and G1 cells; 48 h later and after puromycin selection (5 *μ*g ml^−1^), cells stably expressing NFAT1- or p53-shRNA were identified and used for experiments.

Real-time reverse transcription (RT)--PCR
-----------------------------------------

Primers for amplifying *NFAT1* and *FasL* are shown in [Supplementary Table S2](#sup1){ref-type="supplementary-material"}. Total RNA (200--500 ng) from each sample was used to synthesise cDNA, which was used as a template for PCR. Reactions were prepared in triplicate and the conditions were as follows: 95 °C for 3 min, followed by 45 cycles of 95 °C for 20 s, 63 °C for 20 s and 72 °C for 20 s.

Tumour xenograft model
----------------------

Female 6-week-old nude BALB/C mice were purchased from the Institute of Laboratory Animal Sciences (CAMS and PUMC, Beijing, China). Animal experiments were conducted in accordance with the China Medical University Animal Ethics Committee guidelines and approved by the Institutional Review Board of our hospital.

U87 cells (5 × 10^4^ in 5 *μ*l of PBS) were injected intracranially in anaesthetised nude mice. After 10 days, mice with similar tumour bioluminescence were selected and divided into treatment and control groups (*n*=8 per group) and were administered Li~2~CO~3~ (220 mg kg^−1^ day^−1^, per o.s.; Sigma-Aldrich) and/or TMZ (10 mg kg^−g^ day^−1^, per o.s.). Control animals were treated with vehicle. Blood Li levels were analysed weekly, and stabilised at 1.0--1.2 m[M]{.smallcaps} on day 5 after administration. Mice were killed using Euthasol (0.22 ml kg^−1^ i.v.; Delmarva Laboratories, Midlothian, VA, USA) when they exhibited signs of distress.

For subcutaneous tumour models, 1 × 10^6^ G1 cells in 50 *μ*l of PBS were subcutaneously injected into the left flank of anaesthetised nude BALB/C mice; 3 weeks later, when tumours reached a size of 150--160 mm^3^, mice were randomly divided into four groups (*n*=8 per group) and were administered Li, TMZ, TMZ+Li or vehicle. Tumour growth was monitored by measurement with calipers (Precision Instruments Co., Shanghai, China) every 3 days. On day 42 or when tumours reached a size \>1 cm^3^, mice were killed using euthasol. Tumour volume (*V*) was calculated as follows: *V*=*L* × *W*^2^ × 0.5, where *L* is the length and *W* is the width. Tumour weight was recorded at the end of the study.

Immunohistochemistry
--------------------

Paraffin-embedded tumour specimens were cut into 4 *μ*m sections and sections were labelled with primary antibodies against human pSer21-GSK-3*α* (36E9; Cell Signaling Technology) (1 : 100), pSer9-GSK-3*β* (5B3; Cell Signaling Technology; 1 : 50), NFAT1 (1 : 100) and FasL (1 : 50), followed by incubation with horseradish peroxidase-labelled secondary antibody included in an immunohistochemical labelling kit (KIT-5930; MaxVision, Fu Zhou, China). Results from immunohistochemistry were quantified in a blinded fashion as previously described ([@bib20]). Samples were imaged under a BX-51 light microscope (Olympus).

Statistical analysis
--------------------

The Student's *t*-test and one-way analysis of variance were used to evaluate the statistical significance of differences among groups. Differences in survival were analysed with the log-rank test and Kaplan--Meier analysis. Two-tailed *P*--values \<0.05 were considered significant. Fas expression level according to TP53 status were determined from The Cancer Genome Atlas (TCGA) glioma data set (<http://cancergenome.nih.gov/>) as previously described ([@bib9]). SPSS v.19.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 6 (GraphPad Inc., San Diego, CA, USA) software were used for statistical analyses.

Results
=======

Li enhances the cytotoxicity of TMZ against GBM cells
-----------------------------------------------------

Low-dose Li alone had little effect on TP53wt GBM cell viability ([Figure 1A](#fig1){ref-type="fig"}). In contrast, TMZ suppressed MGMT-methylated U87 cell proliferation by 41.9% and MGMT-unmethylated G1 cell proliferation by 21.2% this effect was potentiated by combination with 1.2 m[M]{.smallcaps} Li (*P*\<0.05), resulting in a 70.3 and 59.8% decrease in proliferation of U87 and G1 cells, respectively ([Figure 1B--D](#fig1){ref-type="fig"}). Since there is a lag phase before cell death induced by TMZ, the viability of U87 and G1 cells was also examined 10 days after TMZ and Li treatment with the MTT assay. Li potentiated the inhibitory effect of TMZ even after a longer incubation time ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}), including inhibition of neurosphere formation (by 3.3- to 4-fold; [Figure 1E](#fig1){ref-type="fig"}). However, the combinational effects of TMZ and Li were insignificant in TP53mut U251 and G2 cells ([Supplementary Figure S1B and C](#sup1){ref-type="supplementary-material"}).

Combined treatment with TMZ and Li leads to apoptosis of GBM cells
------------------------------------------------------------------

Li treatment did not increase the rate of cell death ([Figure 1A, F and G](#fig1){ref-type="fig"}), whereas TMZ combined with Li increased the percentage of cells with sub-G0 DNA content by 1.6- to 2.4-fold relative to the TMZ-only group ([Figure 1F](#fig1){ref-type="fig"}). Furthermore, low-dose Li had a minor effect on apoptosis, as determined by annexin-V staining and the TUNEL assay. However, the rate of apoptosis was increased by 9.3- and 2.2-fold upon TMZ administration alone in U87 and G1 cells, respectively, while combined treatment increased the rate by 9.8- to 16-fold ([Figures 1G](#fig1){ref-type="fig"} and [2A](#fig2){ref-type="fig"}). This was accompanied by changes in nuclear morphology, a decrease in nuclear volume, chromatin condensation and nuclear fragmentation in TP53wt GBM cells ([Figure 2B](#fig2){ref-type="fig"}), which are features of dying cells. However, Li did not enhance the apoptosis-inducing effect of TMZ in TP53mut U251 and G2 cells ([Supplementary Figure S1B--E](#sup1){ref-type="supplementary-material"}).

FasL is upregulated by TMZ and Li treatment and is correlated with GSK-3 inhibition and NFAT1nuclear translocation
------------------------------------------------------------------------------------------------------------------

To investigate the mechanism by which combined TMZ and Li treatment increased TP53wt GBM cell death, we first examined GSK-3 activity by western blotting using antibodies against inactive GSK-3 (i.e., phosphorylated at serines 21 and 9 of GSK-3*α* and -3*β*, respectively) and those that recognise GSK-3*α*/*β* irrespective of phosphorylation state. Treatment with TMZ or Li alone increased pGSK-3 level by 1- to 2-fold, while combined treatment had a more potent effect, inducing a 4- to 5-fold increase ([Figure 2C](#fig2){ref-type="fig"}).

We then examined the intracellular localisation of NFAT1 in TP53wt GBM cells by immunocytochemistry and confocal microscopy. Consistent with previous reports describing increased nuclear NFAT levels upon inhibition of GSK-3 activity ([@bib12]; [@bib16]), treatment with either TMZ or Li increased NFAT1 nuclear translocation, an effect that was enhanced by combined treatment ([Figure 2D](#fig2){ref-type="fig"}). These results were confirmed by western blot analysis of cytoplasmic and nuclear proteins: total NFAT1 levels were similar in both fractions from control cells ([Figure 2E--H](#fig2){ref-type="fig"}), but were slightly reduced in the cytoplasmic fraction of TMZ- and/or Li-treated U87 ([Figure 2E and F](#fig2){ref-type="fig"}) or G1 ([Figure 2G and H](#fig2){ref-type="fig"}) cells. On the other hand, nuclear NFAT1 levels were increased after the combined treatment, resulting in a 7.7- to 14.7-fold increase in nuclear/cytoplasmic NFAT1 ratios.

We next investigated whether the increase in NFAT1 nuclear translocation stimulated FasL expression by real-time RT--PCR and western blotting. Consistent with our previous study ([@bib20]), combined treatment with TMZ and Li increased FasL expression by 36.5--47.9-fold at both the mRNA and protein levels in U87 ([Figure 2I](#fig2){ref-type="fig"}) and G1 ([Figure 2J](#fig2){ref-type="fig"}) cells. Moreover, in agreement with previous reports ([@bib39]), Fas receptor expression was upregulated by 8--9-fold in TP53wt GBM cells but not in TP53mut GBM cells upon exposure to TMZ (data not shown).

p53 status influences apoptosis induced by TMZ+Li
-------------------------------------------------

According to the TCGA glioma data set, TP53wt gliomas have higher Fas expression than TP53mut gliomas ([Figure 3A](#fig3){ref-type="fig"}). p53 knockdown was associated with downregulation of Fas ([Figure 3B](#fig3){ref-type="fig"}) and suppressed TMZ+Li-induced U87 cell death ([Figure 3C--F](#fig3){ref-type="fig"}). Similar results were obtained in G1 cells (data not shown). These results indicate that p53 status determines the apoptotic response of glioma cells to TMZ+Li.

NFAT1 knockdown attenuates GBM cell death induced by TMZ+Li
-----------------------------------------------------------

To determine whether the changes in NFAT1/FasL expression and localisation in response to TMZ+Li treatment were responsible for TP53wt GBM cell death, we generated U87 and G1 cell lines in which NFAT1 expression was stably knocked down with specific shRNA. The downregulation of NFAT1 expression was confirmed by RT--PCR and western blotting ([Figure 4A](#fig4){ref-type="fig"}). In the absence of NFAT1 ([Figure 4B](#fig4){ref-type="fig"}), the effects of TMZ and Li on TP53wt GBM cells were attenuated relative to control cells; that is, the suppression of cell proliferation ([Figure 4C and D](#fig4){ref-type="fig"}) and induction of cell death ([Figure 4E--G](#fig4){ref-type="fig"}) were reduced. Moreover, FasL expression was downregulated in U87 ([Figure 4H](#fig4){ref-type="fig"}) and G1 ([Figure 4I](#fig4){ref-type="fig"}) cells treated with shRNA against NFAT1. The results were confirmed using a different shRNA targeting NFAT1 (data not shown). These findings indicate a direct role for NFAT1 in TP53wt GBM cell death induced by TMZ+Li.

FasL neutralisation suppresses apoptosis induced by TMZ+Li
----------------------------------------------------------

To clarify the role of FasL in TMZ+Li-induced apoptosis, U87 and G1 cells were pre-treated with anti-FasL neutralising antibody or non-immune IgG prior to TMZ+Li administration. FasL neutralisation inhibited TMZ+Li-induced apoptosis, as determined by the MTT and TUNEL assays, cell counts and sub-G0 analysis ([Figure 5A--D](#fig5){ref-type="fig"}). These results indicate that TMZ+Li induces TP53wt GBM cell apoptosis via NFAT1/FasL signalling.

TMZ combined with Li prevents tumour growth *in vivo*
-----------------------------------------------------

Administration of TMZ+Li prolonged survival in mice with intracranial tumours: the median survival times were 22±0.46, 24±3.54 and 31±3.53 days for control, Li-only and TMZ-only groups, respectively ([Figure 6A](#fig6){ref-type="fig"}) and 46±2.36 days for the TMZ+Li group (*P*\<0.05, TMZ+Li *vs* single drug). The combined treatment also reduced subcutaneous tumour growth rate; after 21 days of treatment, tumour volumes for the control, Li alone, TMZ alone and TMZ+Li groups were 649±198, 557±165, 364±110 and 63±43 mm^3^, respectively (*P*\<0.001; [Figure 6B](#fig6){ref-type="fig"}). The combined treatment increased the rate of apoptosis of GBM cells, as determined by the TUNEL assay ([Figure 6C](#fig6){ref-type="fig"}); moreover, it induced the upregulation of pGSK-3*α* ([Figure 6D](#fig6){ref-type="fig"}), pGSK-3*β* ([Figure 6E](#fig6){ref-type="fig"}) and FasL ([Figure 6G](#fig6){ref-type="fig"}) and increased the nuclear translocation of NFAT1 ([Figure 6F](#fig6){ref-type="fig"}) *in vivo*.

Discussion
==========

Survival rates in GBM patients are low due to the poor performance of existing treatments. TMZ is widely used as the first-line drug but its efficacy is limited and transient due to the genetic heterogeneity of GBM cells ([@bib11]; [@bib43]), leading to chemoresistance and treatment failure. Enhancing the cytotoxicity of TMZ can potentially overcome this problem. Previous studies have shown that cell death in gliomas induced by TMZ is due to apoptosis ([@bib39]; [@bib44]); however, this is dependent on TP53 status. In TP53wt GBM cells, TMZ stimulates Fas receptor expression and activates the Fas apoptotic pathway, while in TP53mut GBM cells, it triggers the intrinsic mitochondrial apoptotic pathway ([@bib39]). It is conceivable that in TP53wt cells, activators of Fas/FasL signalling increase the efficacy of TMZ.

We previously found that hyperactivation of NFAT1, which is highly expressed in GBM cells, induces FasL expression and tumour cell death, mimicking AICD in mature lymphocytes ([@bib20]; [@bib41]). In T cells, fibroblasts, and neurons, NFAT1 activation induces apoptosis ([@bib16]; [@bib32]). Although NFAT1 can act as an oncogene or a tumour suppressor depending on cell and tissue type ([@bib32]), cell death induced by NFAT1 hyperactivation has been observed in several tumours, including neuroblastoma and Burkitt's lymphoma ([@bib3]; [@bib37]). Thus, activation of the NFAT1/FasL pathway is clinically significant in GBM. NFAT1 activity is negatively regulated by GSK-3 ([@bib12]); inhibiting GSK-3 activity could in turn activate NFAT1. It has been reported that inhibiting GSK-3 induces glioma cell death ([@bib27]; [@bib26]) via activation of c-MYC ([@bib27]). Interestingly, c-MYC expression is regulated by NFAT1 ([@bib33]). Thus, inhibition of GSK-3 activity may lead to upregulation of c-MYC expression ([@bib27]) via hyperactivation of NFAT1. Moreover, as a regulator of *FasL* gene transcription, c-MYC-induced apoptosis requires functional FasL ([@bib7]; [@bib23]; [@bib24]). Therefore, NFAT1 hyperactivation induces c-MYC overexpression; NFAT1 and c-MYC may cooperatively upregulate FasL expression, leading to glioma cell death. These data provide evidence of a GBM cell death regulatory network involving GSK-3 and NFAT1.

Li is an inhibitor of GSK-3 that acts via multiple signalling pathways ([@bib46]). Chronic exposure to Li inhibits GSK-3 activity, induces nuclear translocation of NFATs, increases FasL levels and leads to apoptosis in neurons ([@bib16]). Li has also been shown to decrease glioma cell invasion and proliferation via GSK-3 inhibition ([@bib34]; [@bib10]; [@bib15]). However, this requires a high concentration (\>5 m[M]{.smallcaps}), which can cause permanent brain damage ([@bib46]). Here we found that low-dose Li (1.2 m[M]{.smallcaps}) alone moderately inhibited GSK-3, activated NFAT1 and upregulated FasL expression. However, consistent with previous studies ([@bib34]; [@bib15]), these effects were not sufficiently strong to alter GBM cell viability and proliferation *in vitro* and *in vivo*. Moreover, the apoptotic effect of Li-induced FasL requires adequate Fas levels. We speculated that the effects of Li could be potentiated by co-administration of a drug such as TMZ, which could activate the GSK-3/NFAT1/Fas/FasL apoptotic pathway. Although it provides a mechanistic basis of TMZ resistance, TMZ can activate AKT, resulting in phosphorylation and deactivation of GSK-3 in GBM cells ([@bib42]; [@bib47]). According to TCGA, Fas is expressed at higher levels in TP53wt as compared with TP53mut gliomas. We demonstrated that clinically relevant concentrations of TMZ (70 *μ*[M]{.smallcaps}) increased pGSK-3 and Fas levels, which resulted in nuclear translocation of NFAT1 and potentiation of the effects of Li. Furthermore, the combination of TMZ and Li significantly enhanced GBM cell death mainly through hyperactivation of NFAT1 and upregulation of Fas/FasL *in vitro* and *in vivo*. However, we found that the combinational effect of TMZ and Li was insignificant in TP53mut U251 and primary G2 cells ([@bib8]; [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Moreover, *p53* knockdown reduced Fas expression and inhibited TMZ+Li-induced apoptosis in TP53wt GBM cells ([Figure 3](#fig3){ref-type="fig"}). Thus, TP53wt exerts a strong positive effect on TMZ+Li-induced Fas/FasL cell death; in its absence, TMZ may only trigger the less efficient mitochondrial apoptotic pathway that is not potentiated by Li ([@bib39]).

In this study, the median survival time was 46 days for tumour-bearing mice receiving combinatorial treatment, which was 15 days longer than those treated with TMZ alone; moreover, 87.5% (7 of 8) of these mice survived more than 40 days, with one (12.5%) surviving more than 60 days. Our results are comparable to other studies of mice treated with combinatorial therapies using U87 cells that survived 4--26.5 days longer than mice treated with TMZ alone ([@bib2]; [@bib31]; [@bib25]; [@bib36]). However, since these studies used different strains of mice, different doses of TMZ, U87 cells with different genetic manipulations and variable end points, caution should be exercised when comparing the results.

Li has been used for over 100 years for the treatment of mood disorders and depression ([@bib46]). It is also ideal for the treatment of GBM for the following reasons. Firstly, GBM is associated with a higher risk of mood disturbance -- especially depression -- compared with other cancers ([@bib38]; [@bib1]). Secondly, Li can restore white blood cells after radio- and chemotherapy and also boost immunoglobulins and enhance natural killer cell activity ([@bib46]). Since GBM patients are often immunocompromised after radiotherapy/chemotherapy, Li can be effective in restoring immune function.

Our results indicate that a subset of GBM patients may benefit from combined treatment with Li and TMZ. Li enhanced the cytotoxicity of TMZ in TP53wt tumours independent of *MGMT* promoter status -- that is, in *MGMT*-methylated U87 and *MGMT*-unmethylated G1 cells, although U87 cells were more sensitive than G1 cells to TMZ treatment ([Figure 1](#fig1){ref-type="fig"}). According to data from TCGA and our patient cohort (63 GBM cases), 71.4--85.2% of GBMs are TP53wt. Consistent with previous reports ([@bib6]), both data sets revealed that TP53wt GBMs often harbour non-mutated *IDH*, non-mutated *ATRX* and mutated *TERT* promoters ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}), all of which predict unfavourable prognosis. Although the relationship between TP53 status and radiotherapy/chemotherapy sensitivity is still debated ([@bib14]; [@bib22]), our therapeutic approach could potentially benefit the more than two-thirds of GBM patients harbouring TP53wt ([@bib35]; [@bib14]).

Conclusion
==========

Temozolomide and low-dose Li potently activated NFAT1/FasL signalling and induced TP53wt GBM cell death *in vitro* and *in vivo*. The combination of these two drugs could thus represent a novel therapeutic strategy for treating a subset of GBM patients.
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![**Temozolomide combined with Li decreases TP53wt GBM cell viability and inhibits proliferation.** (**A**) U87 cell viability in the presence of increasing Li concentrations at 48 h, as determined with the MTT assay (left). Cell death was detected by propidium iodide staining and flow cytometry analysis in U87 cells treated with indicated Li concentrations for indicated times (right). (**B**) U87 and G1 cell viability in the presence of 70 *μ*[M]{.smallcaps} TMZ combined with different concentrations of Li at 48 h, as determined with the MTT assay. GBM cells were left untreated or were treated with TMZ (70 *μ*[M]{.smallcaps}), LiCl (1.2 m[M]{.smallcaps}) or TMZ+Li. (**C**) Viability of U87 and G1 cells as determined by the MTT assay at indicated time points. (**D**) Representative micrographs of U87 cells (left). Scale bar=50 *μ*m. Cell counts following 48 h treatment with TMZ, LiCl or TMZ+Li (right). (**E**) Neurospheres of U87 and G1 cells were labelled with an antibody against the glioma stem cell (GSC) marker CD133. U87 and G1 GSCs were grown under neurosphere culture conditions in the absence or presence of TMZ (70 *μ*[M]{.smallcaps}), LiCl (1.2 m[M]{.smallcaps}) or TMZ+Li for 7 days and the number of neurospheres was counted. Upper: representative images of G1 and U87 neurospheres. (**F**) Analysis of cell death by flow cytometry 48 h after treatment. The fraction of cells in sub-G0 is shown in the graphs. (**G**) Cells were labelled with fluorescein isothiocyanate-conjugated annexin-V and analysed by flow cytometry. Graphs (left) showing annexin-V staining of U87 cells are representative of three independent experiments. Results are presented as mean±s.e., of triplicate samples from three independent experiments. \**P*\<0.05, \*\**P*\<0.01.](bjc201789f1){#fig1}

![**Combining TMZ and Li reduces GSK-3 activity, promotes nuclear translocation of NFAT1 and induces FasL expression and cell death in TP53wt GBM cells.** (**A**) TUNEL assay for detection and quantification of apoptotic cells after 48 h of treatment with TMZ (70 *μ*[M]{.smallcaps}), LiCl (1.2 m[M]{.smallcaps}) or TMZ+Li in U87 and G1 cells. (**B**) Representative transmission electron micrographs of U87 cells left untreated or treated with TMZ+Li for 48 h. Transmission electron microscopy was used to evaluate morphological changes in U87 cells after TMZ+Li treatment. Drug treatment altered the nuclear morphology and caused chromatin condensation (red arrows) and nuclear fragmentation (yellow arrows) in U87 cells, consistent with dying cells. Scale bar=1 *μ*m. (**C**) Western blot (left) and quantitative (right) analyses of inactive GSK-3 (pSer21/9-GSK-3*α*/*β*) in U87 and G1 cells treated with TMZ, LiCl or TMZ+Li. (**D**) Representative confocal micrographs showing NFAT1 expression in U87 and G1 cells, as detected by immunocytochemistry. Nuclei were counterstained with Hoechst 33342. Scale bar=25 *μ*m. (**E**--**H**) Western blot analysis of NFAT1 in total, cytoplasmic and nuclear protein fractions from control or treated U87 (**E**) and G1 (**G**) cells. Hsp90 and lamin B1 were used as loading controls for the cytoplasmic and nuclear fractions, respectively. The nuclear/cytoplasmic ratio of NFAT1 in U87 (**F**) and G1 (**H**) cells are shown. (**I**, **J**) FasL mRNA and protein expression, as determined by real-time RT--PCR (left) and western blotting (right), respectively, in control or treated U87 (**I**) and G1 (**J**) cells. Graphs show mean values of triplicate samples from three independent experiments. \**P*\<0.05, \*\**P*\<0.01.](bjc201789f2){#fig2}

![**TP53 status influences TMZ+Li-induced apoptosis.** (**A**) Fas expression as reported in TCGA was compared between TP53wt and TP53mut glioma. HGG, high-grade glioma. (**B**) Loss of p53 expression by shRNA-mediated knockdown in U87 cells and consequent downregulation of Fas expression, as determined by western blotting. (**C**) Quantitative analysis of cell proliferation with or without *p53* knockdown following treatment with TMZ+Li. Scale bar=50 *μ*m. (**D**) Quantitative analysis of apoptotic cells based on PI incorporation and detection by flow cytometry 48 h after treatment with TMZ+Li and *p53* knockdown. (**E**) Detection of apoptosis with the TUNEL assay in control and p53-deficient cells treated with TMZ+Li. Scale bar=20 *μ*m. (**F**) FasL expression in control and *p53*-deficient U87 cells treated with TMZ+Li, as determined by western blotting. Graphs show the means of triplicate samples from three independent experiments. \**P*\<0.05, \*\**P*\<0.01.](bjc201789f3){#fig3}

![**TMZ+Li-induced TP53wt GBM cell death is NFAT1-dependent.** (**A**) PCR (left) and western blot (right) analyses showing knockdown of *NFAT1* in U87 cells by transfection of specific shRNA. (**B**) Confocal micrographs of NFAT1 expression in control and *NFAT1*-silenced U87 cells treated with TMZ (70 *μ*[M]{.smallcaps})+LiCl (1.2 m[M]{.smallcaps}), as determined by immunocytochemistry. Scale bar=25 *μ*m. (**C**, **D**) MTT assay (**C**) and quantitative analysis of viability (**D**) in control and *NFAT1*-silenced cells treated with TMZ+Li. Scale bar=50 *μ*m. (**E**, **F**) Analysis of cell death based on annexin-V staining (**E**) and incorporation of PI (**F**) and detection by flow cytometry. *NFAT1* knockdown prevented cell death induced by TMZ+Li. (**G**) Results of the TUNEL assay showing the percentage of apoptotic cells in control and *NFAT1*-silenced cells treated with TMZ+Li. (**H**, **I**) Western blot analysis of FasL expression in control and *NFAT1*-silenced U87 (**H**) and G1 (**I**) cells treated with TMZ+Li. Graphs show the means of triplicate samples from three independent experiments. \**P*\<0.05, \*\**P*\<0.01.](bjc201789f4){#fig4}

![**FasL neutralisation significantly inhibits TMZ+Li-induced TP53wt GBM cell death.** (**A**, **B**) The decrease in cell viability and proliferation induced by TMZ+Li was abrogated by FasL neutralisation, as determined by the MTT assay (**A**) and cell counts (**B**). Scale bar=50 *μ*m. (**C**) Cell death was evaluated by flow cytometry after 48 h of treatment with TMZ+Li. Cells were pre-incubated with non-immune IgG or FasL neutralising antibody. The percentage of cells in the sub-G0 phase is shown in the graphs. (**D**) Results of the TUNEL assay showing the percentage of apoptotic control and FasL-neutralised cells treated with TMZ+Li. Graphs show the means of triplicate samples from three independent experiments. \**P*\<0.05, \*\**P*\<0.01.](bjc201789f5){#fig5}

![**TMZ combined with Li inhibits tumour growth *in vivo*.** (**A**) Kaplan--Meier survival plots for intracranial tumour-bearing mice treated with Li, TMZ or TMZ+Li. The log-rank test revealed longer survival times for mice treated with TMZ+Li as compared with those treated with either drug alone or control animals. (**B**) Subcutaneous tumour growth in mice treated with Li, TMZ or TMZ+Li. Tumour growth rate (left) and final tumour weight (right) were reduced by TMZ+Li treatment as compared with either drug alone or the control. (**C**) Results of the TUNEL assay showing induction of GBM cell death *in vivo* by treatment with TMZ+Li. (**D**--**G**) Immunohistochemical detection of increased pSer21-GSK-3*α* (**D**) and pSer9-GSK-3*β* (**E**) levels, nuclear translocation of NFAT1 (**F**) and FasL expression (**G**) *in vivo* by combined treatment of TMZ and Li. \**P*\<0.05, \*\**P*\<0.01. Scale bar=50 *μ*m.](bjc201789f6){#fig6}
